The Technical AnalystExchange: EURONEXT Industry: Biotechnology
Neovacs SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
-9.24% 0.180
America/New_York / 17 mai 2024 @ 11:25
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0632 mill |
| EPS: | -24.86 |
| P/E: | -0.0100 |
| Earnings Date: | Oct 02, 2019 |
| SharesOutstanding: | 0.352 mill |
| Avg Daily Volume: | 0.0131 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0100 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0100 | industry: PE -7.48 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
-0.0021 (-101.18%) -0.182 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
0.0967 - 0.263 ( +/- 46.19%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | 0.180 (-9.24% ) |
| Volume | 0.0724 mill |
| Avg. Vol. | 0.0131 mill |
| % of Avg. Vol | 553.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALNEV.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALNEV.PA
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.